JPH04308556A - Method for racemizing optically active benzyl alcohol derivative - Google Patents

Method for racemizing optically active benzyl alcohol derivative

Info

Publication number
JPH04308556A
JPH04308556A JP9977691A JP9977691A JPH04308556A JP H04308556 A JPH04308556 A JP H04308556A JP 9977691 A JP9977691 A JP 9977691A JP 9977691 A JP9977691 A JP 9977691A JP H04308556 A JPH04308556 A JP H04308556A
Authority
JP
Japan
Prior art keywords
isomer
acid
optically active
butylamino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9977691A
Other languages
Japanese (ja)
Inventor
Yasuo Ito
伊藤 安夫
Hideo Kato
日出男 加藤
Shingo Yasuda
安田 信吾
Keiko Saito
斎藤 惠子
Sakae Kurata
倉田 栄
Susumu Nagasaki
長崎 進
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Japan Co Ltd
Original Assignee
Hokuriku Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokuriku Pharmaceutical Co Ltd filed Critical Hokuriku Pharmaceutical Co Ltd
Priority to JP9977691A priority Critical patent/JPH04308556A/en
Publication of JPH04308556A publication Critical patent/JPH04308556A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PURPOSE:To readily racemize the (+)-isomer in optically active alpha-[(t-butylamino) methyl]-2-chloro-4-hydroxybenzyl alcohol and obtain the (-)-isomer by treating the aforementioned (+)-isomer with an acid such as hydrochloric acid. CONSTITUTION:The (+)-isomer which has hardly any uses in optically active alpha-[(t-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol expressed by the formula or a mixture containing the (+)-isomer in a high proportion is preferably heated with hydrochloric acid, sulfuric acid, methanesulfonic acid, trifluoroacetic acid, p-toluenesufonic acid, etc., to produce the racemic modification thereof. The (-)-isomer is then separated from the resultant racemic modification by optical resolution and used as a metratonic agent or a urinary bladder relaxant.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は、光学活性なベンジルア
ルコール誘導体のラセミ化方法に関し、更に詳しくは、
次式(I)
[Field of Industrial Application] The present invention relates to a method for racemizing optically active benzyl alcohol derivatives, and more specifically, to
The following formula (I)

【化1】 で示される光学活性なα−〔(tert−ブチルアミノ
)メチル〕−2−クロロ−4−ヒドロキシベンジルアル
コールを酸で処理し、そのラセミ体を製造する方法に関
する。
The present invention relates to a method for producing a racemate of optically active α-[(tert-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol represented by the following formula with an acid.

【0002】0002

【従来の技術】本発明に係わる光学活性なベンジルアル
コール誘導体のラセミ化方法は、これまで全く知られて
いない。
BACKGROUND OF THE INVENTION A method for racemizing optically active benzyl alcohol derivatives according to the present invention has not been known so far.

【0003】0003

【発明が解決しようとする課題】先に本発明者等は、前
記式(I)で示される新規な(−)−α−〔(tert
−ブチルアミノ)メチル〕−2−クロロ−4−ヒドロキ
シベンジルアルコール及びその塩類、並びにその子宮弛
緩剤,膀胱弛緩剤としての用途を見い出した。
[Problems to be Solved by the Invention] The present inventors have previously discovered a novel (-)-α-[(tert
-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol and its salts, and their use as uterine relaxants and bladder relaxants.

【0004】この式(I)で示される化合物の製造に当
たっては、そのラセミ体を光学分割している。
[0004] In producing the compound represented by formula (I), its racemic form is optically resolved.

【0005】この分割法は、(−)−異性体と(+)−
異性体を1:1の割合で含むラセミ体から光学分割によ
り(−)−異性体を得る方法であり、目的の(−)−異
性体を得た後の母液から回収される(+)−異性体ある
いは(+)−異性体の割合の多い混合物は、再利用され
ることなく廃棄せざるを得なかった。
[0005] This separation method separates (-)-isomer and (+)-isomer.
This is a method of obtaining the (-)-isomer by optical resolution from a racemate containing isomers at a ratio of 1:1, and the (+)- isomer is recovered from the mother liquor after obtaining the desired (-)-isomer. Isomers or mixtures with a high proportion of (+)-isomers had to be discarded without being reused.

【0006】この従来廃棄されていた(+)−異性体あ
るいは(+)−異性体の割合の多い混合物をラセミ化さ
せてラセミ体を得、それを製造原料として再利用するこ
とは、子宮弛緩剤あるいは膀胱弛緩剤として有用な(−
)−異性体を効率的に得ることができるという産業上大
きな価値を有するものである。
[0006] It is possible to racemize the conventionally discarded (+)-isomer or a mixture with a high proportion of (+)-isomer to obtain a racemate and reuse it as a manufacturing raw material. (-
)-isomers can be obtained efficiently, which has great industrial value.

【0007】[0007]

【課題を解決するための手段】本発明者等は、前述の事
情を鑑み鋭意研究した結果、前記式(I)で示される光
学活性なα−〔(tert−ブチルアミノ)メチル〕−
2−クロロ−4−ヒドロキシベンジルアルコールを酸で
処理することによりラセミ化反応が進行することを見い
出し、本発明を完成させた。
[Means for Solving the Problem] As a result of intensive research in view of the above-mentioned circumstances, the present inventors have discovered that the optically active α-[(tert-butylamino)methyl]-
The present invention was completed based on the discovery that the racemization reaction progresses by treating 2-chloro-4-hydroxybenzyl alcohol with an acid.

【0008】本発明の製造方法において用いられる酸と
しては、塩酸,硫酸,メタンスルホン酸,トリフルオロ
酢酸,p−トルエンスルホン酸等が挙げられ、これらの
酸は水溶液あるいは含水メタノール,エタノール,n−
プロパノール,イソプロパノール等の含水アルコール溶
液として反応に用いることができ、これらの酸は、前記
式(I)で示される光学活性なα−〔(tert−ブチ
ルアミノ)メチル〕−2−クロロ−4−ヒドロキシベン
ジルアルコール1当量に対して、2当量以上使用するの
が好ましい。
Examples of acids used in the production method of the present invention include hydrochloric acid, sulfuric acid, methanesulfonic acid, trifluoroacetic acid, and p-toluenesulfonic acid.
These acids can be used in the reaction as a hydrous alcohol solution such as propanol or isopropanol, and these acids can be used as optically active α-[(tert-butylamino)methyl]-2-chloro-4- It is preferable to use 2 or more equivalents per 1 equivalent of hydroxybenzyl alcohol.

【0009】また、反応は室温から溶媒の還流温度まで
の範囲で行われるが、このラセミ化反応は、室温では長
時間を要するため、加熱するのが好ましい。
[0009] The reaction is carried out at a temperature ranging from room temperature to the reflux temperature of the solvent, but since this racemization reaction requires a long time at room temperature, it is preferable to heat the reaction.

【0010】0010

【実施例】以下、本発明を実施例によって説明するが、
本発明はこれらの例の特定の細部に限定されるものでは
ない。
[Examples] The present invention will be explained below with reference to Examples.
The invention is not limited to the specific details of these examples.

【0011】実施例1 α−〔(tert−ブチルアミノ)メチル〕−2−クロ
ロ−4−ヒドロキシベンジルアルコール・L−酒石酸塩
(HPLCにて(+)−異性体:(−)−異性体=9:
1の混合物)2.02gを2N塩酸20mlに溶解後、
75℃で6時間攪拌した。反応液を冷却後、炭酸カリウ
ムにてアルカリ性とし、析出結晶を濾取した。得られた
結晶を水洗,乾燥して、(±)−α−〔(tert−ブ
チルアミノ)メチル〕−2−クロロ−4−ヒドロキシベ
ンジルアルコールの無色結晶1.05gを得た。本結晶
はHPLCにて(+)−異性体:(−)−異性体=1:
1の混合物であることが確認された。 <HPLC測定条件> 波長  :  220nm カラム:  オボムコイド ULTRON ES−OV
M移動相:  pH6.5  0.02Mリン酸Buf
fer・MeOH(21:4) 本結晶を常法に従い塩酸塩となし、イソプロパノールと
イソプロピルエーテルの混液から再結晶して、融点17
8〜179℃の無色プリズム晶を得た。
Example 1 α-[(tert-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol L-tartrate ((+)-isomer: (-)-isomer= 9:
After dissolving 2.02 g of the mixture of 1) in 20 ml of 2N hydrochloric acid,
The mixture was stirred at 75°C for 6 hours. After cooling the reaction solution, it was made alkaline with potassium carbonate, and the precipitated crystals were collected by filtration. The obtained crystals were washed with water and dried to obtain 1.05 g of colorless crystals of (±)-α-[(tert-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol. This crystal was determined by HPLC as (+)-isomer: (-)-isomer = 1:
It was confirmed that it was a mixture of 1. <HPLC measurement conditions> Wavelength: 220 nm Column: Ovomucoid ULTRON ES-OV
M mobile phase: pH 6.5 0.02M phosphoric acid Buf
fer.MeOH (21:4) This crystal was converted into a hydrochloride salt according to a conventional method, and recrystallized from a mixture of isopropanol and isopropyl ether to give a melting point of 17.
Colorless prism crystals having a temperature of 8 to 179°C were obtained.

【0012】実施例2 α−〔(tert−ブチルアミノ)メチル〕−2−クロ
ロ−4−ヒドロキシベンジルアルコール・L−酒石酸塩
(HPLCにて(+)−異性体:(−)−異性体=9:
1の混合物)4.00gを2N塩酸20mlに溶解後、
75℃で6時間攪拌した。以下、実施例1と同様に処理
して(±)−α−〔(tert−ブチルアミノ)メチル
〕−2−クロロ−4−ヒドロキシベンジルアルコールの
無色結晶2.11gを得た。本結晶はHPLC(測定条
件は実施例1と同様)にて(+)−異性体:(−)−異
性体=1:1の混合物であることが確認された。本結晶
を常法に従い塩酸塩となし、イソプロパノールとイソプ
ロピルエーテルの混液から再結晶して無色プリズム晶を
得た。本品は実施例1で得られたものと融点及びIRが
一致した。
Example 2 α-[(tert-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol L-tartrate (by HPLC (+)-isomer: (-)-isomer= 9:
After dissolving 4.00 g of the mixture of 1) in 20 ml of 2N hydrochloric acid,
The mixture was stirred at 75°C for 6 hours. Thereafter, the same treatment as in Example 1 was carried out to obtain 2.11 g of colorless crystals of (±)-α-[(tert-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol. This crystal was confirmed by HPLC (measurement conditions were the same as in Example 1) to be a mixture of (+)-isomer: (-)-isomer = 1:1. This crystal was converted into a hydrochloride salt according to a conventional method, and recrystallized from a mixture of isopropanol and isopropyl ether to obtain colorless prism crystals. This product had the same melting point and IR as that obtained in Example 1.

【0013】実施例3 (+)−α−〔(tert−ブチルアミノ)メチル〕−
2−クロロ−4−ヒドロキシベンジルアルコール・L−
酒石酸塩2.00gを2N塩酸20mlに溶解後、75
℃で4時間攪拌した。以下、実施例1と同様に処理して
(±)−α−〔(tert−ブチルアミノ)メチル〕−
2−クロロ−4−ヒドロキシベンジルアルコールの無色
結晶1.03gを得た。本結晶はHPLC(測定条件は
実施例1と同様)にて、(+)−異性体:(−)−異性
体=1:1の混合物であることが確認された。本結晶を
常法に従い塩酸塩となし、イソプロパノール及びイソプ
ロピルエーテルの混液から再結晶して無色プリズム晶を
得た。本品は実施例1で得られたものと融点及びIRが
一致した。
Example 3 (+)-α-[(tert-butylamino)methyl]-
2-chloro-4-hydroxybenzyl alcohol L-
After dissolving 2.00 g of tartrate in 20 ml of 2N hydrochloric acid, 75
The mixture was stirred at ℃ for 4 hours. Thereafter, in the same manner as in Example 1, (±)-α-[(tert-butylamino)methyl]-
1.03 g of colorless crystals of 2-chloro-4-hydroxybenzyl alcohol were obtained. This crystal was confirmed by HPLC (measurement conditions were the same as in Example 1) to be a mixture of (+)-isomer: (-)-isomer = 1:1. This crystal was converted into a hydrochloride salt according to a conventional method, and recrystallized from a mixture of isopropanol and isopropyl ether to obtain colorless prism crystals. This product had the same melting point and IR as that obtained in Example 1.

【0014】参考例1 (−)−α−〔(tert−ブチルアミノ)メチル〕−
2−クロロ−4−ヒドロキシベンジルアルコール・L−
酒石酸塩2.00gを2N塩酸20mlに溶解後、75
℃で4時間攪拌した。以下、実施例1と同様に処理して
、(±)−α−〔(tert−ブチルアミノ)メチル〕
−2−クロロ−4−ヒドロキシベンジルアルコールの無
色結晶1.06gを得た。本結晶はHPLC(測定条件
は実施例1と同様)にて、(+)−異性体:(−)−異
性体=1:1の混合物であることが確認された。本結晶
を常法に従い塩酸塩となし、イソプロパノール及びイソ
プロピルエーテルの混液から再結晶して無色プリズム晶
を得た。本品は実施例1で得られたものと融点及びIR
が一致した。
Reference Example 1 (-)-α-[(tert-butylamino)methyl]-
2-chloro-4-hydroxybenzyl alcohol L-
After dissolving 2.00 g of tartrate in 20 ml of 2N hydrochloric acid, 75
The mixture was stirred at ℃ for 4 hours. Thereafter, the same treatment as in Example 1 was carried out to obtain (±)-α-[(tert-butylamino)methyl]
1.06 g of colorless crystals of -2-chloro-4-hydroxybenzyl alcohol were obtained. This crystal was confirmed by HPLC (measurement conditions were the same as in Example 1) to be a mixture of (+)-isomer: (-)-isomer = 1:1. This crystal was converted into a hydrochloride salt according to a conventional method, and recrystallized from a mixture of isopropanol and isopropyl ether to obtain colorless prism crystals. This product has the same melting point and IR as that obtained in Example 1.
matched.

【0015】[0015]

【発明の効果】本発明の方法によれば、子宮弛緩剤ある
いは膀胱弛緩剤として有用な(−)−α−〔(tert
−ブチルアミノ)メチル〕−2−クロロ−4−ヒドロキ
シベンジルアルコールを効率的に得ることが可能となる
Effects of the Invention According to the method of the present invention, (-)-α-[(tert
-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol can be obtained efficiently.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】光学活性なα−〔(tert−ブチルアミ
ノ)メチル〕−2−クロロ−4−ヒドロキシベンジルア
ルコールを酸で処理することを特徴とする、そのラセミ
体の製造方法。
1. A method for producing a racemate of optically active α-[(tert-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol, which comprises treating the same with an acid.
JP9977691A 1991-04-05 1991-04-05 Method for racemizing optically active benzyl alcohol derivative Pending JPH04308556A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9977691A JPH04308556A (en) 1991-04-05 1991-04-05 Method for racemizing optically active benzyl alcohol derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9977691A JPH04308556A (en) 1991-04-05 1991-04-05 Method for racemizing optically active benzyl alcohol derivative

Publications (1)

Publication Number Publication Date
JPH04308556A true JPH04308556A (en) 1992-10-30

Family

ID=14256358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9977691A Pending JPH04308556A (en) 1991-04-05 1991-04-05 Method for racemizing optically active benzyl alcohol derivative

Country Status (1)

Country Link
JP (1) JPH04308556A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779261A1 (en) * 1995-12-13 1997-06-18 Uop Continuous process for racemization of benzylic alcohols, ethers, and esters by solid acid catalyst
CN104098478A (en) * 2013-04-08 2014-10-15 安徽贝克联合制药有限公司 Aminoalcohol resolution method
JP2021100930A (en) * 2009-01-15 2021-07-08 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779261A1 (en) * 1995-12-13 1997-06-18 Uop Continuous process for racemization of benzylic alcohols, ethers, and esters by solid acid catalyst
JP2021100930A (en) * 2009-01-15 2021-07-08 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
CN104098478A (en) * 2013-04-08 2014-10-15 安徽贝克联合制药有限公司 Aminoalcohol resolution method
CN104098478B (en) * 2013-04-08 2017-05-17 安徽贝克联合制药有限公司 Aminoalcohol resolution method

Similar Documents

Publication Publication Date Title
JP4795435B2 (en) Method for producing esomeprazole and salts thereof
US11897843B2 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
AU2002330774B2 (en) Process for resolution of tamsulosin
JP2007516934A (en) Novel process for preparing (+)-(S)-clopidogrel bisulfate form-I
JP2001525817A (en) Novel intermediates and methods for their preparation
JPH04308556A (en) Method for racemizing optically active benzyl alcohol derivative
JP2004511476A (en) Method for producing R (+) α-lipoic acid
JP2011098975A (en) Chiral pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenylalanine and method for producing crystal structure transformation product thereof
AU605253B2 (en) Optically active oxo-isoindolinyl derivatives
HU178248B (en) Process for producing 1-2-amino-butanol salts of phenyl-glycine derivatives,and in a given case for deliberating the amino acid from the salt
JP2977237B2 (en) Optical resolution method of dropropidine
KR20010079913A (en) METHOD FOR PRODUCING (-)-α-(DIFLUOROMETHYL)ORNITHINE-MONOHYDROCHLORIDE MONOHYDRATE
KR880002236B1 (en) A process for isolating levamisole from tetramisole
JP2917495B2 (en) Method for producing optically active 1,2-propanediamine
JPS63145256A (en) Production of optically active homophenylalanine and intermediate therefor
JP2616211B2 (en) Preparation of optically active 1,2-propanediamine
ES2324984T3 (en) A PROCEDURE FOR THE PREPARATION OF (R) OR (S) -5- (2-AMINOPROPIL) -2-METOKI-BENZENO-SULFONAMIDE ENANTIOMERICALLY PURE.
JP3316917B2 (en) New phenylalanine salt crystals and their production
SU408943A1 (en) METHOD OF OBTAINING L-WINE ACID
JP2712669B2 (en) Preparation of optically active 1,2-propanediamine
JP4109446B2 (en) Process for producing pure trans-2-[(α-methylbenzyl) amino] cyclopentanol as a diastereoisomer
JPH05502027A (en) R(+) - Method for producing terodiline and salts thereof
KR20030008708A (en) Method of preparing optically active mandelic acid
JPH021429A (en) Production of optically active 1-methyl-3-phenylpropylamine
JPH023627A (en) Production of optically active 1-methyl-3-phenylpropylamine